May 9, 2008
YM Biosciences Reports Fiscal Third Quarter 2008 Operational and Financial Results
“During the quarter we continued to advance nimotuzumab globally, leveraging co-operative efforts of multiple partners and other licensees of the drug”
YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported operational and financial results for its third quarter of ... via Med Ad News
Comments
|
Joined: May 11, 2008
Comments: 46
|
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Millions to die in China from lung disease: report | 3 hr | old china | 47 |
| Health officials: Don't panic over chromium 6 -... | Thu | bigbub | 27 |
| Pictorial warnings on tobacco products in India... | Thu | sam | 4 |
| No title | Wed | DJDan | 1 |
| Five-Year Project Will Examine Health Effects O... | Oct 8 | heyits me | 9 |
| Two drugs don't boost lung cancer survival: Roche | Oct 8 | gdpawel | 1 |
| Red wine decreases the risk of lung cancer | Oct 8 | Musician | 2 |
